Total Payments
$12,316
2024 Payments
$170.86
Companies
14
Transactions
58
Medicare Patients
2,861
Medicare Billing
$334,603
Payment Breakdown by Category
Research$7,684 (62.4%)
Travel$3,042 (24.7%)
Food & Beverage$1,440 (11.7%)
Education$149.86 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7,684 | 11 | 62.4% |
| Travel and Lodging | $3,042 | 11 | 24.7% |
| Food and Beverage | $1,440 | 33 | 11.7% |
| Education | $149.86 | 3 | 1.2% |
Payments by Type
Research
$7,684
11 transactions
General
$4,632
47 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $5,005 | 3 | $0 (2018) |
| INTUITIVE SURGICAL, INC. | $3,583 | 29 | $0 (2024) |
| F. Hoffmann-La Roche AG | $2,679 | 8 | $0 (2021) |
| GlaxoSmithKline, LLC. | $185.78 | 2 | $0 (2023) |
| TESARO, Inc. | $171.07 | 4 | $0 (2019) |
| Foundation Medicine, Inc. | $129.93 | 2 | $0 (2023) |
| Gen-Probe Sales & Service, Inc. | $122.00 | 1 | $0 (2022) |
| Baxter Healthcare | $109.13 | 3 | $0 (2023) |
| Seagen Inc. | $96.00 | 1 | $0 (2023) |
| Genentech USA, Inc. | $90.69 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $170.86 | 7 | INTUITIVE SURGICAL, INC. ($170.86) |
| 2023 | $616.88 | 10 | Foundation Medicine, Inc. ($129.93) |
| 2022 | $246.03 | 3 | Gen-Probe Sales & Service, Inc. ($122.00) |
| 2021 | $2,154 | 7 | F. Hoffmann-La Roche AG ($2,137) |
| 2020 | $623.37 | 5 | F. Hoffmann-La Roche AG ($541.83) |
| 2019 | $179.99 | 7 | Intuitive Surgical, Inc. ($165.49) |
| 2018 | $8,077 | 15 | Merck Sharp & Dohme Corporation ($5,005) |
| 2017 | $247.61 | 4 | TESARO, Inc. ($120.00) |
All Payment Transactions
58 individual payment records from CMS Open Payments — Page 2 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $184.66 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER • Category: BioOncology | ||||||
| 01/08/2021 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $16.75 | General |
| Category: SURGERY | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $369.38 | Research |
| Study: A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM • Category: BioOncology | ||||||
| 11/06/2020 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $28.67 | General |
| Category: SURGERY | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $172.45 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER • Category: BioOncology | ||||||
| 08/12/2020 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $24.25 | General |
| Category: SURGERY | ||||||
| 01/14/2020 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $28.62 | General |
| Category: SURGERY | ||||||
| 12/17/2019 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $4.85 | General |
| Category: SURGERY | ||||||
| 11/13/2019 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: SURGERY | ||||||
| 10/19/2019 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $3.25 | General |
| Category: SURGERY | ||||||
| 05/21/2019 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $78.77 | General |
| Category: SURGERY | ||||||
| 05/14/2019 | TESARO, Inc. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: ONCOLOGY | ||||||
| 03/27/2019 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: SURGERY | ||||||
| 02/15/2019 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $9.62 | General |
| Category: SURGERY | ||||||
| 09/21/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | — | In-kind items and services | $539.00 | Research |
| Study: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Subjects with Advanced Endometrial Cancer • Category: ONCOLOGY | ||||||
| 09/21/2018 | TESARO, Inc. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | — | In-kind items and services | $297.40 | Research |
| Study: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Subjects with Advanced Endometrial Cancer • Category: ONCOLOGY | ||||||
| 06/14/2018 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $674.22 | General |
| Category: SURGERY | ||||||
| 06/14/2018 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $646.60 | General |
| Category: SURGERY | ||||||
| 06/14/2018 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $421.47 | General |
| Category: SURGERY | ||||||
| 06/09/2018 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $223.23 | General |
| Category: SURGERY | ||||||
| 05/24/2018 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $23.00 | General |
| Category: SURGERY | ||||||
| 05/22/2018 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $357.44 | General |
| Category: SURGERY | ||||||
| 05/17/2018 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $409.20 | General |
| Category: SURGERY | ||||||
| 05/17/2018 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $234.52 | General |
| Category: SURGERY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Subjects with Advanced Endometrial Cancer | Merck Sharp & Dohme Corporation | $5,005 | 3 |
| A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER | F. Hoffmann-La Roche AG | $2,310 | 7 |
| A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | F. Hoffmann-La Roche AG | $369.38 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 546 | 5,221 | $418,086 | $61,699 |
| 2022 | 26 | 781 | 24,004 | $912,336 | $105,467 |
| 2021 | 21 | 701 | 10,130 | $495,802 | $82,527 |
| 2020 | 28 | 833 | 21,911 | $679,508 | $84,910 |
Total Patients
2,861
Total Services
61,266
Medicare Billing
$334,603
Procedure Codes
95
All Medicare Procedures & Services
95 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2023 | 22 | 22 | $71,742 | $13,586 | 18.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 36 | 114 | $78,204 | $11,065 | 14.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 84 | 144 | $33,622 | $8,319 | 24.7% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 17 | 33 | $34,188 | $5,970 | 17.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 36 | 36 | $18,324 | $4,402 | 24.0% |
| 86304 | Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | Office | 2023 | 44 | 157 | $19,468 | $3,201 | 16.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 14 | 52 | $17,368 | $2,501 | 14.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 26 | 171 | $17,955 | $1,973 | 11.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 39 | 157 | $9,734 | $1,625 | 16.7% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 17 | 34 | $27,098 | $1,609 | 5.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 14 | 22 | $5,126 | $1,332 | 26.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 58 | 154 | $2,926 | $1,286 | 43.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 42 | 167 | $5,845 | $1,271 | 21.7% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 11 | 49 | $7,448 | $1,081 | 14.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 11 | 11 | $3,608 | $989.30 | 27.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 14 | 14 | $4,620 | $694.68 | 15.0% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 17 | 3,400 | $10,200 | $399.84 | 3.9% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 15 | 410 | $50,020 | $341.23 | 0.7% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 14 | 38 | $266.00 | $31.42 | 11.8% |
| J3490 | Unclassified drugs | Office | 2023 | 15 | 36 | $324.00 | $22.20 | 6.9% |
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2022 | 38 | 38 | $123,918 | $26,090 | 21.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 38 | 191 | $131,026 | $19,483 | 14.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 75 | 120 | $27,144 | $7,824 | 28.8% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2022 | 14 | 5,720 | $51,480 | $7,800 | 15.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 50 | 50 | $25,450 | $5,607 | 22.0% |
About Dr. Charles Anderson, M.D
Dr. Charles Anderson, M.D is a Obstetrics & Gynecology healthcare provider based in Eugene, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2008. The National Provider Identifier (NPI) number assigned to this provider is 1215191259.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Anderson, M.D has received a total of $12,316 in payments from pharmaceutical and medical device companies, with $170.86 received in 2024. These payments were reported across 58 transactions from 14 companies. The most common payment nature is "" ($7,684).
As a Medicare-enrolled provider, Anderson has provided services to 2,861 Medicare beneficiaries, totaling 61,266 services with total Medicare billing of $334,603. Data is available for 4 years (2020–2023), covering 95 distinct procedure/service records.
Ad
Practice Information
- Specialty Obstetrics & Gynecology
- Other Specialties Gynecologic Oncology
- Location Eugene, OR
- Active Since 07/17/2008
- Last Updated 08/05/2021
- Taxonomy Code 207V00000X
- Entity Type Individual
- NPI Number 1215191259
Products in Payments
- KEYTRUDA (Biological) $5,005
- Da Vinci Surgical System (Device) $3,583
- TECENTRIQ (Biological) $2,137
- Tecentriq (Biological) $541.83
- ZEJULA (Drug) $264.30
- APTIMA (Device) $122.00
- TIVDAK (Biological) $96.00
- JEMPERLI (Biological) $92.55
- Avastin (Biological) $90.69
- MYCHOICE CDX (Device) $79.67
- TISSEEL (Device) $58.33
- ADEPT (Device) $30.80
- Xtandi (Drug) $28.19
- FLOSEAL (Device) $20.00
- LYNPARZA (Drug) $16.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Obstetrics & Gynecology Doctors in Eugene
Amy Mccarthy, Md, MD
Obstetrics & Gynecology — Payments: $6,796
Obstetrics & Gynecology $6,796
Dr. Elizabeth Mccorkle, Md, MD
Obstetrics & Gynecology — Payments: $6,034
Obstetrics & Gynecology $6,034
Dr. Johanna Higdon, Md, MD
Obstetrics & Gynecology — Payments: $4,776
Obstetrics & Gynecology $4,776
Richard Lee, Md, MD
Obstetrics & Gynecology — Payments: $1,244
Obstetrics & Gynecology $1,244
Brian Wakefield, M.d, M.D
Obstetrics & Gynecology — Payments: $1,142
Obstetrics & Gynecology $1,142
Dr. Sara Gerhards, Md, MD
Obstetrics & Gynecology — Payments: $1,119
Obstetrics & Gynecology $1,119